Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying Therapies

Trial Profile

A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying Therapies

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obicetrapib (Primary)
  • Indications Dyslipidaemias
  • Focus Registrational; Therapeutic Use
  • Acronyms BROADWAY
  • Sponsors NewAmsterdam Pharma
  • Most Recent Events

    • 08 Jan 2024 According to a NewAmsterdam Pharma media release, company began enrolling patients in this trial in January 2022 and completed enrollment in July 2023.
    • 04 Jan 2024 According to a NewAmsterdam Pharma media release, the company expects to report topline data in the fourth quarter of 2024.
    • 31 Aug 2023 Planned End Date changed from 1 May 2024 to 1 Sep 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top